China set to launch drug pricing inspections
May 30, 2016 Category Health, Weekly
China will carry out wide-ranging pricing inspections on drug firms, hospitals and procurement bodies from June 1 till the end of October, the National Development and Reform Commission (NDRC) said. Drug prices have become a hot issue for patients and politicians in China, forcing drug companies to rethink their pricing strategy. Britain’s GlaxoSmithKline (GSK) and AstraZenca, along with China’s Betta Pharmaceuticals, recently agreed to cut prices on specific drugs by as much as 67%. The Commission said the investigations would include drug makers, medical institutions, disease prevention and control centers, blood banks, drug bidding platforms, procurement bodies and industry associations. “The focus will be on abnormal price fluctuations of bulk medicines and various types of drugs,” the NDRC said. China is pursuing an ambitious program of health-care reforms to improve the public health system and to reduce its reliance on drugs from overseas.
- KURT VANDEPUTTE (UMICORE) APPOINTED CHAIRMAN OF THE BOARD OF THE FLANDERS-CHINA CHAMBER OF COMMERCE (FCCC)
- Webinar: “Knowing Your Chinese Partner” – May 26, 2021, 10 am – 12 am
- EMA starts rolling review of CoronaVac, WHO approves Sinopharm vaccine for emergency use
- The Global Times warns not to politicize the Comprehensive Agreement on Investment (CAI)
- Hainan to become biggest duty-free market in the world